Analystreport

Moleculin Biotech (NASDAQ:MBRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.

Moleculin Biotech, Inc.  (MBRX) 
Last moleculin biotech, inc. earnings: 8/16 05:35 pm Check Earnings Report
US:NASDAQ Investor Relations: moleculin.com/investors